Compare ACADIA Pharmaceuticals Inc. (ACAD) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs JetBlue Airways Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while JetBlue Airways Corporation trades at $5.56 (market cap $2.13B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| ACAD | JBLU | |
|---|---|---|
Market Cap | $4.49B | $2.13B |
Sector | Health | Industrials |
52-Week High | $28.06 | $6.46 |
52-Week Low | $20.06 | $4.03 |
Enterprise Value | $3.69B | $9.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
JetBlue (JBLU) trades at $5.72, down 4.98% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The airline faces fundamental challenges with negative net income margins (-7.78%) and ROE (-33.51%) despite a low P/S ratio of 0.24. Recent strategic shifts include expanding premium Mint service in Fort Lauderdale while reducing New York operations to cut costs.
The outlook remains cautious with Wall Street showing limited conviction (19% buy rating) and a consensus price target of $5.12 below current levels. Key risks include persistent losses, high debt levels (debt-to-asset ratio over 50%), and competitive pressures, though lower fuel costs and travel demand provide some sector support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
